MA-PRECISELY
21.6.2022 16:02:10 CEST | Business Wire | Press release
Precisely, the global leader in data integrity, today launched its new Precisely Data Integrity Suite – bringing the latest innovation in data integrity to the market. Announced at the company’s Trust ’22 event, the Data Integrity Suite is composed of seven interoperable SaaS modules that can be deployed individually, or seamlessly combined to deliver exponential value – fuelling businesses with unparalleled levels of trusted data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005275/en/
The announcement comes at the same time as the latest IDC Spotlight paper on “Improving Data Integrity and Trust through Transparency and Enrichment,” shows that only 27% of data professionals say they completely trust their data. With 63% of organizations reporting that higher levels of data integrity make a positive impact on their business metrics 1 , the launch of the new Data Integrity Suite is a timely one.
“Data integrity is an imperative for every business, but the journey to achieving it is different for every organization. With the Precisely Data Integrity Suite, businesses can start anywhere, go at their own pace, and grow value at every step of their unique journey,” said Eric Yau, COO at Precisely. “Our unmatched breadth of data integrity capabilities and enrichment data, combined with our strategic services expertise, means that we can help businesses chart their path to data integrity and lead them along the way.”
The Suite’s Data Integration, Data Observability, and Data Governance modules are available for early access now for businesses looking to build a foundation of accuracy and consistency in their data:
-
Data Integration
:
enables organizations to break down silos by quickly building streaming data pipelines that integrate data from core transaction systems into modern data platforms, driving innovation, and modernizing mission-critical infrastructure
-
Data Observability
:
a new entry from Precisely into this rapidly growing market, proactively and intelligently detects and surfaces data anomalies before they become costly downstream issues that could disrupt business
- Data Governance: delivers a business-friendly framework to find, understand, trust, and leverage critical data across an organization for better outcomes and insights, improved operations, and regulatory compliance
The following modules will join the Data Integrity Suite in the coming months:
-
Data Quality:
delivers data that is accurate, consistent, complete, and fit for purpose across operational and analytical systems
-
Geo Addressing:
unlocks valuable context by verifying, standardizing, cleansing, and geocoding addresses for more informed decision-making
-
Spatial Analytics:
derives and visualizes spatial relationships hidden in data to reveal critical context for better decisions
- Data Enrichment: enriches data with expertly curated datasets containing thousands of attributes for faster, more confident decisions
The Data Integrity Suite delivers access to trusted data at the speed of business and empowers organizations to make fast, confident decisions that drive growth, reduce costs, and manage risk. With a business-friendly user experience, it supports data democratization and self-service access to data for business and data users alike. Its unique Data Integrity Foundation includes a common data catalog that enables each module to build on metadata previously gathered by other modules, combining seamlessly to deliver maximum value to the customer.
“With the launch, Precisely is delivering on the vision they have painted for the market of integrating its capabilities into a modular, interoperable suite,” said Stewart Bond, Research Director at IDC. “Precisely has a strategic blend of technology and services within its portfolio to meet the needs of organizations with legacy and modern data environments that are wanting to compete in a digital-first world.”
“Businesses are increasingly investing in DataOps to continually improve the data they use for analytics and decision-making. The Precisely Data Integrity Suite’s end-to-end, integrated approach to data integration, data governance and quality, as well as location intelligence and data enrichment gives organizations all the tools and agility they need to automate and iterate on the integrity of their data,” said Anjan Kundavaram, CPO at Precisely. “The introduction of the Suite’s Data Observability module is essential for DataOps teams, allowing them to leverage AI and machine learning to gain critical insight into the health of their company’s data, monitor changes to patterns in that data, and proactively resolve potential issues.”
Financial services company, Degroof Petercam, a Precisely customer and participant in the Data Integrity Suite’s early access program, sees clear benefits of the new Data Observability module. “Observability is the missing piece today to give our data stewards access to data discovery insights without having to go to IT for queries or reports.” explains Jean-Paul Otte, Chief Data Officer at Degroof Petercam.
“The portfolio of data integrity assets that Precisely offers is the gold standard for building trusted data,” said Yau. “That same technology, recognized by industry analysts and relied upon by over 12,000 customers to address their data challenges today, is at the heart of the new Precisely Data Integrity Suite – providing the ultimate modular, interoperable, solution for organizations relying on data integrity across both legacy and modern cloud environments.”
Learn more about the new Data Integrity Suite and watch the 90-second video.
Data Integrity Suite Video Embed: To view this piece of content from www.youtube.com, please give your consent at the top of this page.
- IDC Spotlight, sponsored by Precisely, “Improving Data Integrity and Trust Through Transparency and Enrichment” (doc # US49285622, June 2022)
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
